2-Bromopropane → 6-[4-(3,3-Diphenyl-1-propyl)piperazin-1-yl]-2-isopropyl-2,3-dihydro-1H-isoindol-1-one
반응식
[C:1]1([CH:7]([C:26]2[CH:31]=[CH:30][CH:29]=[CH:28][CH:27]=2)[CH2:8][CH2:9][N:10]2[CH2:15][CH2:14][N:13]([C:16]3[CH:24]=[C:23]4[C:19]([CH2:20][NH:21][C:22]4=[O:25])=[CH:18][CH:17]=3)[CH2:12][CH2:11]2)[CH:6]=[CH:5][CH:4]=[CH:3][CH:2]=1.Br[CH:33]([CH3:35])[CH3:34]>>[C:26]1([CH:7]([C:1]2[CH:2]=[CH:3][CH:4]=[CH:5][CH:6]=2)[CH2:8][CH2:9][N:10]2[CH2:11][CH2:12][N:13]([C:16]3[CH:24]=[C:23]4[C:19]([CH2:20][N:21]([CH:33]([CH3:35])[CH3:34])[C:22]4=[O:25])=[CH:18][CH:17]=3)[CH2:14][CH2:15]2)[CH:31]=[CH:30][CH:29]=[CH:28][CH:27]=1참가 물질
3
실험 절차
In the same manner as in Example 51, the title compound (32 mg) was prepared from the compound (50 mg) obtained in Example 50 and 2-bromopropane (148 mg).
출처 및 근거
- ORD 기록
- ord-66ff3f349faa4fa184e209bf9bae9e10
- 출처 데이터셋
- uspto-grants-2003_06